Name: Relias Media
Price range: $

Denosumab Use for the Practicing Oncologist

The U.S. Food and Drug Administration (FDA) has recently approved denosumab for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

Pharmacology Watch

Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.

Finding Optimal Therapy for Gastric Cancer

A trial undertaken by EORTC was designed to determine if neoadjuvant chemotherapy would be successful in the absence of post-surgical chemotherapy in enhancing overall survival in patients with locally advanced gastric cancer. The trial did not accrue sufficient numbers of patients to demonstrate a survival benefit. However, presurgical chemotherapy was associated with a higher rate of complete resection and fewer positive lymph nodes, features that suggest progression-free and overall survival might be favorably affected.

Treating Colon Cancer in Patients with Diabetes

In a retrospective review of consecutive patients with colon cancer, the presence of diabetes mellitus was found to confer negative prognostic information with regard to overall, and cancer-specific, survival. Notably, it was in patients with stage II disease that the presence of diabetes was of most importance.